Drug Trial Radar · NCT04468659
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,400
Planned (sponsor's estimate)
Start
Jul 14, 2020
Primary completion
Dec 21, 2028
Study completion Jan 16, 2031
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- Collaborators
- Alzheimer's Clinical Trials Consortium; Biogen; National Institute on Aging (NIA)
- First posted
- Jul 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). This study will also evaluate the long-term safety and tolerability of lecanemab in participants enrolled in the Extension Phase.
Conditions
- Preclinical Alzheimer's Disease
- Early Preclinical Alzheimer's Disease
Interventions
LecanemabDrug
IV infusion.
PlaceboDrug
IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- A45 Trial: Change From Baseline in Preclinical Alzheimer Cognitive Composite 5 (PACC5) Score at Week 216Time frame: Baseline, Week 216
- A3 Trial: Change From Baseline in Amyloid Positron Emission Tomography (PET) Standard Uptake Value Ratio (SUVr) at Week 216Time frame: Baseline, Week 216
Locations
107 sites in 7 countries. Site status is shown where the registry gives one.
University of Alabama, Birmingham
Birmingham, Alabama
Banner Alzheimer's Institute
Phoenix, Arizona
Banner Sun Health Research Institute
Sun City, Arizona
UCI MIND
Irvine, California
University of Southern California
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Stanford University
Palo Alto, California
Sharp Mesa Vista Hospital
San Diego, California
University of California, San Francisco
San Francisco, California
University of California, Davis
Walnut Creek, California
Yale University School of Medicine
New Haven, Connecticut
Georgetown University
Washington D.C., District of Columbia
Howard University
Washington D.C., District of Columbia
Advanced Clinical Research Network, Corp
Coral Gables, Florida
Brain Matters Research
Delray Beach, Florida
Mayo Clinic Jacksonville
Jacksonville, Florida
K2 Medical Research - The Villages
Lady Lake, Florida
K2 Medical Research, Llc
Maitland, Florida
Gonzalez MD & Aswad MD Health Sciences
Miami, Florida
Wien Center for Clinical Research
Miami Beach, Florida
Renstar Medical Research
Ocala, Florida
Synexus Clinical Research - Orlando
Orlando, Florida
University of South Florida - Health Byrd Alzheimer Institute
Tampa, Florida
Synexus Clinical Research - The Villages
The Villages, Florida
Alzheimer's Research and Treatment Center
Wellington, Florida
Charter Research
Winter Park, Florida
Emory University
Atlanta, Georgia
Columbus Memory Center
Columbus, Georgia
Northwestern University
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Indiana University School of Medicine
Indianapolis, Indiana
University of Kansas
Fairway, Kansas
University of Kentucky
Lexington, Kentucky
Johns Hopkins University
Baltimore, Maryland
Boston University
Boston, Massachusetts
Brigham and Woman's Hospital Center for Alzheimer Research and Treatment
Boston, Massachusetts
Donald S.Marks, M.D.,P.C.
Plymouth, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic, Rochester
Rochester, Minnesota
Washington University, St. Louis
St Louis, Missouri
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.